# Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)

> **NCT06463184** · PHASE1 · WITHDRAWN · sponsor: **H. Lee Moffitt Cancer Center and Research Institute**

## Conditions studied

- Recurrent High-grade Glioma

## Interventions

- **DRUG:** Xevinapant

## Key facts

- **NCT ID:** NCT06463184
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-07-22
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** funding issues
- **Last updated:** 2024-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06463184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06463184, "Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06463184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*